SCHEMBL23064709

SCHEMBL23064709

O=c1c2cc(Cl)ccc2nc(Nc2ccccc2)n1-c1ccccc1Cl

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.48
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
WEE1 P30291 1/20 0.47
LMNA P02545 2/20 0.46
TP53 P04637 1/20 0.46
TUBB4A P04350 1/20 0.46
TUBB P07437 1/20 0.46
TUBA3C P0DPH7 1/20 0.46
TUBA1B P68363 1/20 0.46
TUBA4A P68366 1/20 0.46
TUBB4B P68371 1/20 0.46
TUBB3 Q13509 1/20 0.46
TUBB2A Q13885 1/20 0.46
TUBB8 Q3ZCM7 1/20 0.46
TUBA3E Q6PEY2 1/20 0.46
TUBA1A Q71U36 1/20 0.46
TUBA1C Q9BQE3 1/20 0.46
TUBB6 Q9BUF5 1/20 0.46
TUBB2B Q9BVA1 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30103295 0.90 WEE1 (0.46) KDM4EMEN1KMT2AWEE1LMNA
SCHEMBL23958267 0.90 WEE1 (0.46) KDM4EMEN1KMT2AWEE1LMNA
SCHEMBL23064706 0.89 TUBB4A (0.46) KDM4EMEN1KMT2ALMNATUBB4A
SCHEMBL23064708 0.88 JUN (0.49) KDM4EMEN1KMT2ALMNATP53
SCHEMBL24089978 0.87 TUBB4A (0.48) KDM4EMEN1KMT2ALMNATUBB4A
SCHEMBL24089907 0.85 LMNA (0.55) MEN1KMT2ALMNATP53HTT
SCHEMBL24090094 0.84 TP53 (0.48) KDM4ELMNATP53TUBB4ATUBB
SCHEMBL29623326 0.84 TP53 (0.48) KDM4ELMNATP53TUBB4ATUBB
SCHEMBL23065214 0.83 TUBB4A (0.47) KDM4EMEN1KMT2ALMNATUBB4A
SCHEMBL23065219 0.82 TUBB4A (0.52) KDM4EMEN1KMT2ALMNATUBB4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11352366-B2 2-aminoquinazolinone derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2022-06-07 US disclosed
US-20220143020-A1 2-AMINOQUINAZOLINONE DERIVATIVE SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2022-05-12 US disclosed
US-20210380598-A1 2-AMINOQUINAZOLINONE DERIVATIVE SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2021-12-09 US disclosed
WO-2021039968-A1 2-AMINOQUINAZOLINONE DERIVATIVE 大日本住友製薬株式会社 2021-03-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220143020-A1 2-AMINOQUINAZOLINONE DERIVATIVE CNKSR1, HAX1, CRKL KDM4E 2185/4885MEN1 1124/4885KMT2A 1257/4885
US-20210380598-A1 2-AMINOQUINAZOLINONE DERIVATIVE CNKSR1, HAX1, SLC26A3 KDM4E 1813/4885MEN1 1282/4885KMT2A 967/4885
US-11352366-B2 2-aminoquinazolinone derivative CNKSR1, HAX1, SLC26A3 KDM4E 1813/4885MEN1 1282/4885KMT2A 967/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.